

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number
WO 2004/009579 A1

(51) International Patent Classification⁷: C07D 333/34,
A61K 31/381, A61P 29/00

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/SE2003/001214

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 15 July 2003 (15.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202280-4 19 July 2002 (19.07.2002) SE

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): METE, Antonio
[IT/GB]; AstraZeneca R & D Charnwood, Bakewell Road,
Loughborough, Leicestershire LE11 5RH (GB). WAL-
TERS, Iain [GB/GB]; AstraZeneca R & D Charnwood,
Bakewell Road, Loughborough, Leicestershire LE11 5RH
(GB).

(74) Agent: ASTRAZENECA AB; Global Intellectual Prop-
erty, S-151 85 Södertälje (SE).


Published:

— with international search report

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(I)

(57) Abstract: There are provided novel compounds of formula (I)
wherein R¹, R², R³, R¹⁰, M, Q, T, U, Y, V and W are as defined in the
specification and pharmaceutically acceptable salts thereof; together with
processes for their preparation, compositions containing them and their
use in therapy. The compounds are inhibitors of nitric oxide synthase
and are thereby particularly useful in the treatment or prophylaxis of
inflammatory disease and pain.

WO 2004/009579 A1

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

NOVEL COMPOUNDS

Field of the Invention

- 5 The present invention relates to novel heteroarylalkylamine derivatives, processes for their preparation, compositions containing them and their use in therapy.

Background of the Invention


- 10 Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (eNOS) is involved with smooth muscle relaxation and the regulation of blood pressure
15 and blood flow, whereas the neuronal enzyme (nNOS) appears to be involved in the regulation of various biological functions. Inducible NOS has been particularly implicated in the pathogenesis of inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, *Ann. Rep. Med. Chem.*, 1996, 31, 221 - 230).

20

Considerable effort has been expended in efforts to identify compounds that act as specific inhibitors of one or more isoforms of the enzyme nitric oxide synthase. The use of such compounds in therapy has also been widely claimed.

25 Disclosure of the invention

According to the present invention, there is provided a compound of formula (I)



(I)

wherein:

5 Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C=CH, NO₂, CH₂OH, CHO, COCH₃, NH₂, NHCHO, NHCOCH₃, or NHSO₂CH₃; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

10 T, U and W independently represent CX, N, NR⁹, O or S(O)_m, except that at least one of T, U and W must represent a heteroatom and except that not more than one of T, U and W may represent NR⁹, O or S(O)_m; m represents an integer 0, 1 or 2; and each X group independently represents H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, OH, SH, CN, C=CH, N(R¹¹)₂, NO₂, CH₂OH, CHO, COCH₃ or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

15 V represents NR⁴, O, CH₂, S(O)_n, OCH₂, CH₂O, NR⁴CH₂, CH₂NR⁴, CH₂S(O)_n, S(O)_nCH₂, CH₂CH₂ or CH=CH;

n represents an integer 0, 1 or 2;

20 M represents C, and when M is bonded to a CH₂ moiety in V, then M may also represent N;

R¹⁰ represents H or Me.

Q represents $(\text{CH}_2)_p$ and p represents an integer 0, 1, 2 or 3;

R^1 represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO_2 or NR^5R^6 ; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R^2 and R^3 independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, $-\text{Z}-\text{NR}^7\text{R}^8$, phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF_3 , OCF_3 , CN or NO_2 ;

Z represents $-\text{CO}-$ or a bond;

R^4 and R^{11} independently represent H or C1 to 2 alkyl;

R^5 , R^6 , R^7 and R^8 independently represent H or C1 to 4 alkyl;

R^9 represents H, C1 to 4 alkyl, CHO, COCH_3 , SO_2CH_3 or CF_3 ;

or a pharmaceutically acceptable salt thereof.

The compounds of formula (I) may exist in enantiomeric forms. It is to be understood that all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.

It will be recognised that compounds of formula (I) wherein U, T or W represents CX and X represents OH may exist in the alternative keto tautomeric form. Similarly, compounds of formula (I) wherein U, T or W represents CX and X represents NH may exist in the alternative imino tautomeric form. And similarly, compounds of formula (I) wherein U, T or W represents CX and X represents SH may exist in the alternative thioketo tautomeric form. It is to be understood that all such possible tautomeric forms and mixtures thereof are included within the scope of the invention.

The compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS). In particular, the compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS).

The invention further provides a process for the preparation of compounds of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

According to the invention there is also provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.

Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.

Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of inducible nitric oxide synthase activity is beneficial.

A more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.

A more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of pain.

5

According to the invention, there is also provided a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

10

More particularly, there is also provided a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

15

The compounds of the present invention may also be used advantageously in combination with a second pharmaceutically active substance; particularly in combination with a cyclooxygenase inhibitor; more particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2). Thus, in a further aspect of the invention there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in combination with a COX-2 inhibitor for the treatment of inflammation, inflammatory disease and inflammatory related disorders. And there is also provided a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition, wherein the method comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a COX-2 inhibitor.

20

25

In one embodiment, V in formula (I) represents $S(O)_n$ and n represents 0.


30

In another embodiment, Y in formula (I) represents CN.

In another embodiment, R^1 in formula (I) represents optionally substituted phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N. In a further embodiment, R^1 in formula (I) represents optionally substituted phenyl, pyridyl, thienyl, isoxazolyl, isothiazolyl or thiazolyl. In a yet further embodiment, R^1 in formula (I) represents optionally substituted phenyl.

In one embodiment, one of T, U and W in formula (I) represents S and the other two represent CX and M represents C.

In a particular embodiment, the compounds of formula (I) have the absolute stereochemistry as shown:



(I)

Particular compounds of the invention include:
3-[[[(1S)-2-amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile;
and pharmaceutically acceptable salts thereof.

Unless otherwise indicated, the term "C1 to 4 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 4 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

Unless otherwise indicated, the term "C3 to 6 cycloalkyl" referred to herein denotes a cycloalkyl group having from 3 to 6 carbon atoms. Examples of such groups include cyclopropyl, cyclopentyl and cyclohexyl.

Unless otherwise indicated, the term "C1 to 4 alkoxy" referred to herein denotes a straight or branched chain alkoxy group having from 1 to 4 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy and t-butoxy.

Unless otherwise indicated, the term "halogen" referred to herein denotes fluoro, chloro, bromo and iodo.


Examples of a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N include furan, thiophene, pyridine, thiazole, imidazole, oxazole, triazole, oxadiazole, thiadiazole and pyrimidine.

Examples of a five or six membered saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N include pyrrolidine, tetrahydrofuran, piperidine and piperazine.


Examples of a "C1 to 4 alkyl or C1 to 4 alkoxy optionally further substituted by one or more fluorine atoms" include CH_2F , CHF_2 , CF_3 , CF_3CF_2 , CF_3CH_2 , CH_2FCH_2 , CH_3CF_2 , $\text{CF}_3\text{CH}_2\text{CH}_2$, OCF_3 and OCH_2CF_3 .

According to the invention, we further provide a process for the preparation of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof which comprises:

(a) reaction of a compound of formula (II)




wherein T, U, W, Y and M are as defined in formula (I) and L^1 represents a leaving group, with a compound of formula (III)



(III)


wherein R¹, R², R³, R¹⁰, Q and V are as defined in formula (I); or

(b) reaction of a compound of formula (IV)



(IV)


wherein T, U, W, M, Y and V are as defined in formula (I), with a compound of formula (V)



(V)

wherein R^1 , R^2 , R^3 , R^{10} and Q are as defined in formula (I) and L^2 is a leaving group; or


(c) reaction of a compound of formula (VI)



(VI)


wherein R^1 , R^{10} , Q, T, U, W, M, Y and V are as defined in formula (I) and L^3 is a leaving group,

with a compound of formula (VII)



wherein R^2 and R^3 are as defined in formula (I); or

(d) reduction of a compound of formula (VIII)




(VIII)

wherein R^1 , R^{10} , Q, T, U, W, M, Y and V are as defined in formula (I) and P represents

azide (N_3); or

(e) hydrolysis of a compound of formula (VIII)



(VIII)

5 wherein R^1 , R^{10} , Q, T, U, W, M, Y and V are as defined in formula (I) and P represents an imide group;

and where desired or necessary converting the resultant compound of formula (I), or another
 10 salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

In process (a), the reaction is performed by treating a nucleophile of formula (III) with an
 15 electrophile of formula (II) in an inert solvent. Suitable leaving groups L^1 include sulphonates and halides, particularly fluoride or chloride. The reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate. Suitable organic solvents are those such as N,N-dimethylformamide, N-methyl-2-pyrrolidinone, tetrahydrofuran, acetonitrile and dimethylsulfoxide. The
 20 reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

In process (b), the reactants (IV) and (V) are coupled together in a suitable inert solvent
 25 such as tetrahydrofuran using, for example, Mitsunobu conditions. Thus, for example, the reactants are treated with a phosphine derivative and an azo derivative at a suitable temperature, generally between 0 °C and the boiling point of the solvent. Suitable

phosphine derivatives include triphenylphosphine and tributylphosphine. Suitable azo derivatives include diethyl azodicarboxylate, diisopropyl azodicarboxylate and 1,1'-(azodicarbonyl)dipiperidine. Suitable leaving groups L^2 include hydroxy.

5 Alternatively in process (b), the reaction is performed by treating a nucleophile of formula (IV) with an electrophile of formula (V) in an inert solvent. Suitable leaving groups L^2 include sulphonates and halides, particularly chloride or bromide. The reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate. Suitable organic solvents are those such as N,N-dimethylformamide,
10 N-methyl-2-pyrrolidinone, tetrahydrofuran and dimethylsulfoxide. The reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.

In process (c), the compounds of formulae (VI) and (VII) are reacted together in a suitable inert solvent such as dimethylsulphoxide or tetrahydrofuran. The reaction is generally
15 carried out in the presence of a base. The base may be either an added component or an excess of the amine (VII). Suitable leaving groups L^3 include iodide and p-toluenesulphonate.

In processes (d) and (e), the reactions are carried out using standard conditions that will be
20 well known to the man skilled in the art.

It will be apparent to a person skilled in the art that in the above processes it may be desirable or necessary to protect an amine or hydroxyl or other potentially reactive group. Suitable protecting groups and details of processes for adding and removing such groups may
25 be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

In one preferred embodiment, amine groups are protected as carbamate derivatives, for example, as t-butyloxycarbamates.


30

Specific examples of the use of protecting groups are given in the Examples section.

The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.

- Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed *in vacuo* or by freeze drying. The reaction may also be a metathetical process or it may be carried out on an ion exchange resin.

Compounds of formula (III) may be prepared by reaction of a compound of formula (IX)



20

- wherein R^2 , R^3 and Q are as defined in formula (I), and G represents H, Cl or $NCH_3(OCH_3)$, with an organometallic derivative, R^1-M , wherein R^1 is as defined in formula (I) and M represents a metallic residue such as lithium or magnesium-halide, followed if necessary by reduction. The resulting compound of formula (III) wherein V represents oxygen may then be subsequently converted into compounds of formula (III) wherein V represents sulphur.

25

Compounds of formulae (II), (IV), (V), (VI), (VIII) and (IX) are either known or may be prepared by conventional methods that will be readily apparent to the man skilled in the art.

- 5 Intermediate compounds may be used as such or in protected form. Protecting groups and details of processes for their removal may be found by reference to the standard text "Protective Groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

- 10 The compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.

- The compounds of formula I may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the
15 compounds using conventional techniques, for example, fractional crystallisation, or HPLC.

Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.

- 20 The compounds of formula (I), and their pharmaceutically acceptable salts, enantiomers and racemates, are useful because they possess pharmacological activity in animals. In particular, the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as
25 anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase. In general, compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they show good selectivity for the inhibition of iNOS and/or nNOS in comparison to the inhibition of the endothelial isoform, eNOS.

30

The compounds and their pharmaceutically acceptable salts are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric

oxide synthase forms a contributory part. In particular, the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.

Conditions that may be specifically mentioned are:

- 5 osteoarthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis and other arthritic conditions, inflamed joints;
- eczema, psoriasis, dermatitis or other inflammatory skin conditions such as sunburn;
- inflammatory eye conditions including uveitis, glaucoma and conjunctivitis;
- lung disorders in which inflammation is involved, for example, asthma, bronchitis, chronic
- 10 obstructive pulmonary disease, pigeon fancier's disease, farmer's lung, acute respiratory distress syndrome;
- bacteraemia, endotoxaemia (septic shock), aphthous ulcers, gingivitis, pyresis, pain, meningitis and pancreatitis;
- conditions of the gastrointestinal tract including inflammatory bowel disease, Crohn's disease,
- 15 atrophic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, irritable bowel syndrome, reflux oesophagitis, damage to the gastrointestinal tract resulting from infections by, for example, *Helicobacter pylori*, or from treatments with non-steroidal anti-inflammatory drugs;
- and other conditions associated with inflammation.

20

The compounds may also be useful in the treatment of cancer.

The compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.

25

We are particularly interested in the conditions inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, pain and cancer.

The compounds of formula (I) and their pharmaceutically acceptable salts may also be useful

30 in the treatment or prophylaxis of diseases or conditions in addition to those mentioned above. For example, the compounds may be useful in the treatment of atherosclerosis, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the

immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in the maintenance of pancreatic function in diabetes, in the treatment of vascular complications associated with diabetes and in co-therapy with cytokines, for example TNF or interleukins.

5

The compounds of formula (I) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and AIDS-related
10 dementia, Sydenham's chorea, Parkinson's disease, Tourette's syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, Korsakoff's disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated
15 with premenstrual syndrome (PMS), anxiety and septic shock. Compounds of formula (I) may also be expected to show activity in the prevention and reversal of drug addiction or tolerance such as tolerance to opiates and diazepam, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders and in the induction of labour.

20

We are particularly interested in the conditions stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia, migraine, septic shock and pain.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have
25 suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

30

For the above mentioned therapeutic indications, the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired.

However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.

The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, inhalation, intravenous, topical or other parenteral routes. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988. The pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

According to the invention, we further provide a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

The compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with one of the following therapies: NSAIDS, COX-2 inhibitors, Paracetamol, Tramadol, Corticosteroids, Glucosamine, Doxycyclin, Pralnacasan, MMP inhibitors or Coll-3 inhibitors. The compound of formula (I) and the combination therapy may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.

The invention is illustrated, but in no way limited, by the following examples:

The following abbreviations are used: DMSO (dimethylsulfoxide), DMF (*N,N*-dimethylformamide), THF (tetrahydrofuran).

Example 1

3-[[*(1S)*-2-Amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile oxalate

a) 3-Bromo-5-methyl-2-thiophenecarbonitrile

To a suspension of 3-bromo-5-methyl-2-thiophenecarboxaldehyde (500 mg) in water (10 ml) was added hydroxylamine-O-sulfonic acid (330 mg). The mixture was heated to 50 °C for 12 h and allowed to cool. The mixture was then extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed (brine), dried (MgSO₄), filtered and evaporated to leave the sub-title compound (410 mg) as a brown solid.

¹H NMR 300MHz (CDCl₃) 6.79 (1H, s), 2.54 (3H, s).

b) 1,1-Dimethylethyl [(2*R*)-2-hydroxy-2-phenylethyl]carbamate

(*R*)-α-(Aminomethyl)benzenemethanol (1.70 g) and bis(1,1-dimethylethyl)carbonate (2.98 g) were dissolved in methanol (20 ml) and triethylamine (4.3 ml) added. The mixture was stirred at room temperature for 4 days and then concentrated to leave the sub-title compound as an oil (2.60 g).

¹H NMR 300MHz (CDCl₃) 7.27-7.38 (5H, m), 4.92 (1H, m), 4.83 (1H, m), 3.50 (1H, m), 3.25 (1H, m), 1.45 (9H, s)

c) *S*-[[*(1S)*-2-[[*(1,1*-Dimethylethoxy)carbonyl]amino]-1-phenylethyl] benzenecarbothioate

To a solution of triphenylphosphine (5.75 g) in THF (100 ml) under nitrogen at 0 °C was added diisopropylazodicarboxylate (4.55 ml) dropwise. The mixture was stirred at 0 °C for 45 minutes and then a solution of thiobenzoic acid (3.05 ml) and the product from step (b) (2.60 g) in THF (50 ml) added dropwise at 0 °C. After the addition was complete the mixture was stirred at room temperature for 24 h. The mixture was concentrated and the

residue purified by chromatography (silica, 10% diethyl ether/isohexane as eluent) to give the sub-title compound (3.30 g) as a yellow solid.

¹H NMR 300MHz (CDCl₃) 7.95 (2H, m), 7.56 (1H, m), 7.28-7.44 (7H, m), 4.94 (1H, m),
5 4.75 (1H, bs), 3.70 (2H, m), 1.38 (9H, s).

d) 1,1-Dimethylethyl [(2S)-2-[(2-cyano-5-methyl-3-thienyl)thio]-2-phenylethyl]carbamate
S-[(1S)-2-[[[(1,1-Dimethylethoxy)carbonyl]amino]-1-phenylethyl] benzenecarbothioate
(210 mg) was dissolved in 7M ammonia in methanol (10 ml) and stirred under nitrogen for
10 2 h. The solution was evaporated to dryness and the residue dissolved in dry DMF (10 ml).
To this solution was added the product from step (a) (120 mg) followed by caesium
carbonate (195 mg). The reaction mixture was stirred for 24 h, poured into water and
extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with
brine and dried (MgSO₄). The solvent was evaporated off and the residue purified by
15 chromatography (silica, 20% ethyl acetate/isohexane as eluent) to give the sub-title
compound as an oil (65 mg).

MS (APCI+ve) ^{m/z} 275 [M+H-BOC]⁺.

20 e) 3-[[[(1S)-2-Amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile oxalate
To a solution of the product from step (d) (65 mg) in methanol (5 ml) was added 4M HCl
in dioxane (5 ml). The mixture was stirred at 20 °C for 2 h and the solvent was removed *in*
vacuo. The residue was partitioned between aqueous sodium bicarbonate and ethyl acetate.
The aqueous phase was extracted with ethyl acetate (2 x 50 ml) and the combined extracts
25 were washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue
was dissolved in ethyl acetate and a solution of oxalic acid in diethyl ether added. The
solution was filtered and dried to give the title compound as a white solid (11 mg).

MS (APCI+ve) ^{m/z} 275 [M(+H)]⁺.

¹H NMR 400MHz (DMSO-*d*₆) 7.38 (5H, m), 7.19 (1H, s), 4.74 (1H, m), 3.48 (1H, m), 3.28 (1H, m), 2.50 (3H, s).

Screens

5 The pharmacological activity of compounds according to the invention was tested in the following screens.

Screen 1

10 The activity of compounds of formula (I), or a pharmaceutically acceptable salt, enantiomer or racemate thereof, may be screened for nitric oxide synthase inhibiting activity by a procedure based on that of Förstermann *et al.*, Eur. J. Pharm., 1992, 225, 161-165. Nitric oxide synthase converts ³H-L-arginine into ³H-L-citrulline which can be separated by cation
15 exchange chromatography and quantified by liquid scintillation counting.

Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal
20 bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm³ flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO₂.

Nitric oxide synthase is produced by cells in response to interferon-γ (IFNγ) and
25 lipopolysaccharide (LPS). The medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml IFNγ. After a period of 17-20 hours in culture, harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium. Cells are collected by centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing
30 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1% (v/v) Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 mg/ml), soya bean

trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethanesulphonyl fluoride (50 mg/ml).

For the assay, 25 μ l of substrate cocktail (50 mM Tris-HCl (pH 7.5 at 20 °C), 400 μ M NADPH, 20 μ M flavin adenine dinucleotide, 20 μ M flavin mononucleotide, 4 μ M tetrahydrobiopterin, 12 μ M L-arginine and 0.025 mCi L-[³H] arginine) is added to wells of a 96 well filter plate (0.45 μ m pore size) containing 25 μ l of a solution of test compound in 50 mM Tris-HCl. The reaction is started by adding 50 μ l of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 μ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.

Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W. 150 μ l of a 25% aqueous slurry of Dowex 50W (Na⁺ form) is added to the assay after which the whole is filtered into 96 well plates. 75 μ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.

In a typical experiment basal activity is 300 dpm per 75 μ l sample which is increased to 1900 dpm in the reagent controls. Compound activity is expressed as IC₅₀ (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an IC₅₀ (50% inhibitory concentration) of 10 μ M, is tested as a standard to verify the procedure. Compounds are tested at a range of concentrations and from the inhibitions obtained IC₅₀ values are calculated. Compounds that inhibit the enzyme by at least 25% at 100 μ M are classed as being active and are subjected to at least one retest.

In the above screen, the compound of Example 1 was tested and gave an IC₅₀ value of less than 10 μ M indicating that it is expected to show useful therapeutic activity.

Screen 2

Recombinant human NO synthases (iNOS, eNOS & nNOS) were expressed in *E. coli* and lysates were prepared in Hepes buffer (pH 7.4) containing co-factors (FAD, FMN, H₄B), protease inhibitors, lysozyme and the detergent, CHAPS. These preparations were used, at suitable dilution, to assess inhibition of the various isoforms. Inhibition of NOS was determined by measuring the formation of L-[³H]citrulline from L-[³H]arginine using an adaptation of the method of Förstermann *et al.*⁹ Enzyme assays were performed in the presence of 3 µM [³H]arginine, 1 mM NADPH and other co-factors required to support NOS activity (FAD, FMN, H₄B, calmodulin, Ca²⁺). Since various NOS inhibitors have been reported to exhibit slow binding kinetics, or to inactivate the enzyme in a time dependent manner, enzyme and inhibitor were pre-incubated for 60 min in the presence of NADPH before addition of arginine to initiate the reaction. Incubations continued for a further 60 min before the assays were quenched and [³H]citrulline separated from unreacted substrate by chromatography on Dowex-50W resin in a 96-well format.

In the above screen, the compound of Example 1 was tested and gave an IC₅₀ value of less than 10 µM against the iNOS enzyme indicating that it is expected to show useful therapeutic activity.

Screen 3

Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.

The human colorectal carcinoma cell line, DLD-1 (obtained from the European Collection of Animal Cell Culture - cell line number 90102540) was routinely grown in RPMI 1640 supplemented with 10%(v/v) foetal bovine serum, and 2mM L-glutamine, at 37 °C in 5% CO₂.

Nitric oxide synthase was induced in cells by addition of medium containing human recombinant gamma-IFN (1000 units/ml), TNF-alpha (200 U/ml), IL-6 (200 U/ml) and

IL-1-beta (250 U/ml). After incubation for 18 hours at 37 °C, the medium was removed and the cells washed with warm phosphate buffered saline. Cells were incubated for a further 5 hours at 37 °C / 5% CO₂ in RPMI 1640 containing 100µM L-arginine and 100µM verapamil-HCl in the presence and absence of test compounds.

5


Nitrite accumulation was determined by mixing an equal volume of culture media with Griess reagent (10 mg/ml sulphanilamide, 1 mg *N*-(1-naphthyl)ethylenediamine in 1 ml 2.5% (v/v) phosphoric acid). Inhibition in the presence of compounds was calculated relative to the nitrite levels produced by untreated cells. IC₅₀ values were estimated from a
10 semi-log plot of % inhibition versus concentration of compound.

In the above screen, the compound of Example 1 was tested and gave an IC₅₀ value of less than 100 µM indicating that it is expected to show useful therapeutic activity.

15

CLAIMS:

1. A compound of formula (I)



(I)

wherein:

10 Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C=CH, NO₂, CH₂OH, CHO, COCH₃, NH₂, NHCHO, NHCOCH₃, or NHSO₂CH₃; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

15 T, U and W independently represent CX, N, NR⁹, O or S(O)_m, except that at least one of T, U and W must represent a heteroatom and except that not more than one of T, U and W may represent NR⁹, O or S(O)_m; m represents an integer 0, 1 or 2; and each X group independently represents H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, OH, SH, CN, C=CH, N(R¹¹)₂, NO₂, CH₂OH, CHO, COCH₃ or NHCHO; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

20 V represents NR⁴, O, CH₂, S(O)_n, OCH₂, CH₂O, NR⁴CH₂, CH₂NR⁴, CH₂S(O)_n, S(O)_nCH₂, CH₂CH₂ or CH=CH;

n represents an integer 0, 1 or 2;

M represents C, and when M is bonded to a CH₂ moiety in V, then M may also represent N;

R¹⁰ represents H or Me.

5 Q represents (CH₂)_p and p represents an integer 0, 1, 2 or 3;

R¹ represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from
10 halogen, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CN, NO₂ or NR⁵R⁶; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R² and R³ independently represent H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, -Z-NR⁷R⁸, phenyl or a
15 five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF₃, OCF₃, CN or NO₂;

20 Z represents -CO- or a bond;

R⁴ and R¹¹ independently represent H or C1 to 2 alkyl;

R⁵, R⁶, R⁷ and R⁸ independently represent H or C1 to 4 alkyl;


25

R⁹ represents H, C1 to 4 alkyl, CHO, COCH₃, SO₂CH₃ or CF₃;

or a pharmaceutically acceptable salt thereof.


2. A compound of formula (I), according to Claim 1, wherein V represents $S(O)_n$ and n represents 0.
- 5 3. A compound according to Claim 1 or 2 wherein Y represents CN.
4. A compound of formula (I), according to Claim 1, which is:
3-[[[(1S)-2-amino-1-phenylethyl]thio]-5-methyl-2-thiophenecarbonitrile;
or a pharmaceutically acceptable salt, enantiomer or racemate thereof.
- 10 5. A compound of formula (I), according to any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use as a medicament.
6. A pharmaceutical composition comprising a compound of formula (I) according to any
15 one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
7. The use of a compound of formula (I) according to any one of Claims 1 to 4, or a
pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the
20 treatment or prophylaxis of human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
8. The use as claimed in Claim 7 wherein it is predominantly inducible nitric oxide synthase
that is inhibited.
- 25 9. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.
- 30 10. The use as claimed in Claim 9 wherein the disease is inflammatory bowel disease.
11. The use as claimed in Claim 9 wherein the disease is rheumatoid arthritis.

12. The use as claimed in Claim 9 wherein the disease is osteoarthritis.
13. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a
5 pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the
treatment or prophylaxis of pain.
14. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a
pharmaceutically acceptable salt thereof, in combination with a COX-2 inhibitor, in the
10 manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.
15. A method of treating, or reducing the risk of, human diseases or conditions in which
inhibition of nitric oxide synthase activity is beneficial which comprises administering a
therapeutically effective amount of a compound of formula (I), as defined in any one of
15 Claims 1 to 4, or a pharmaceutically acceptable salt thereof, to a person suffering from, or at
increased risk of, such diseases or conditions.
16. A method of treating, or reducing the risk of, inflammatory disease in a person suffering
from, or at risk of, said disease, wherein the method comprises administering to the person a
20 therapeutically effective amount of a compound of formula (I), as defined in any one of
Claims 1 to 4, or a pharmaceutically acceptable salt, enantiomer or racemate thereof.
17. A process for the preparation of a compound of formula (I), as defined in any one of
Claims 1 to 4, or a pharmaceutically acceptable salt, enantiomer or racemate thereof,
25 wherein the process comprises:
- (a) reaction of a compound of formula (II)



(II)


wherein T, U, W, Y and M are as defined in Claim 1 and L^1 represents a leaving group,
with a compound of formula (III)



(III)


wherein R^1 , R^2 , R^3 , R^{10} , Q and V are as defined in Claim 1; or

(b) reaction of a compound of formula (IV)



(IV)

wherein T, U, W, M, Y and V are as defined in Claim 1,
with a compound of formula (V)




(V)

wherein R^1 , R^2 , R^3 , R^{10} and Q are as defined in Claim 1 and L^2 is a leaving group; or

(c) reaction of a compound of formula (VI)

5



(VI)

wherein R^1 , R^{10} , Q , T , U , W , M , Y and V are as defined in Claim 1 and L^3 is a leaving group,

10 with a compound of formula (VII)




(VII)

wherein R^2 and R^3 are as defined in Claim 1; or

15

(d) reduction of a compound of formula (VIII)




(VIII)

wherein R^1 , R^{10} , Q, T, U, W, M, Y and V are as defined in Claim 1 and P represents azide (N_3); or

5

(e) hydrolysis of a compound of formula (VIII)



(VIII)

10 wherein R^1 , R^{10} , Q, T, U, W, M, Y and V are as defined in Claim 1 and P represents an imide group;

and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of
 15 formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/01214

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 333/34, A61K 31/381, A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0373836 A1 (ELI LILLY AND COMPANY), 20 June 1990 (20.06.90)	1-17

A	WO 0162713 A1 (ASTRAZENECA AB), 30 August 2001 (30.08.01)	1-17

A	WO 0162704 A1 (ASTRAZENECA AB), 30 August 2001 (30.08.01)	1-17

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 October 2003

Date of mailing of the international search report

24-10-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

NEBIL GECER/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

06/09/03

International application No.

PCT/SE 03/01214

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	0373836	A1	20/06/90	SE	0373836 T3	
				AT	102920 T	15/04/94
				CA	2005173 A	14/06/90
				DE	68913930 D,T	14/07/94
				JP	2218661 A	31/08/90
				US	4902710 A	20/02/90
<hr/>						
WO	0162713	A1	30/08/01	AU	1043401 A	08/05/01
				AU	3431301 A	03/09/01
				CA	2387087 A	03/05/01
				EP	1242914 A	25/09/02
				EP	1263714 A	11/12/02
				GB	0004149 D	00/00/00
				JP	2003513365 T	08/04/03
				JP	2003523992 T	12/08/03
				US	2003105161 A	05/06/03
<hr/>						
WO	0162704	A1	30/08/01	AU	1043501 A	08/05/01
				AU	3431501 A	03/09/01
				BR	0108613 A	12/11/02
				CA	2387643 A	03/05/01
				CA	2397234 A	30/08/01
				CN	1411435 T	16/04/03
				EP	1229860 A	14/08/02
				EP	1263711 A	11/12/02
				GB	0004153 D	00/00/00
				JP	2003512130 T	02/04/03
				JP	2003523988 T	12/08/03
				NO	20024014 A	25/09/02
				US	2003158185 A	21/08/03

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01214

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **15-16**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☒ Claims Nos.: **1-3 and 5-17**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/01214

Box I.1

Claims 15-16 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule. 39.1.(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Box I:2

Present claims 1-3 and 5-17 relate to an extremely large number of possible compounds. Disclosure within the meaning of Articles 5 and 6 PCT is to be found, however, for only a very small proportion of the compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the exemplified compounds and closely related homologous compounds, i.e. those compounds of formula (I) wherein U = sulphur and T, W, M = carbon.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)